An investigation on behalf of investors of Immune Design Corp. (NASDAQ: IMDZ) in connection with the proposed takeover was announced and NASDAQ: IMDZ stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 03/07/2019 -- The takeover of Immune Design Corp. is under investigation concerning potential wrongdoing.
Investors who purchased shares of Immune Design Corp. (NASDAQ: IMDZ) and currently hold any of those NASDAQ: IMDZ shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain officers and directors of Immune Design Corp. breached their fiduciary duties owed to NASDAQ: IMDZ investors in connection with the proposed acquisition.
Seattle, WA based Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. On February 21, 2019, Merck (NYSE: MRK) and Immune Design (NASDAQ:IMDZ) announced that the companies have entered into an agreement under which Merck, through a subsidiary, will acquire Immune Design for $5.85 per share in cash for an approximate value of $300 million.
However, given that at least one analyst has set the high target price for NASDAQ: IMDZ shares at $6.00 per share and given that NASDAQ: IMDZ shares reached in July 2017 as high as $12.85 per share, the investigation concerns whether the offer is unfair to NASDAQ: IMDZ stockholders. More specifically, the investigation concerns whether the Immune Design Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Shares of Immune Design Corp. (NASDAQ: IMDZ) closed on March 6, 2019, at $5.83 per share.
Those who are current investors in Immune Design Corp. (NASDAQ: IMDZ) shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels